

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule for Persons 6 Months of Age and Older



The following tables provide COVID-19 vaccination schedules based on age, health status, and product. For detailed guidance see [Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC](#).

Table 1a. **For Most People (those who are NOT moderately to severely immunocompromised)**

Bivalent Moderna COVID-19 Vaccine: * Monovalent Moderna vaccine is no longer recommended and should not be used. Vaccine type: mRNA			
Age	Vaccination History	Bivalent Vaccine Schedule†	Administer
6 months through 5 years‡§	Unvaccinated: 0 doses	2 doses. Administer: • Dose 1 now • Dose 2 at least 4–8 weeks¶ after Dose 1	0.25 mL/25 µg from the vial with a blue cap and gray label border
	1 dose of bivalent vaccine	1 dose. Administer: • Dose 2 at least 4–8 weeks¶ after Dose 1	
	At least 2 doses of bivalent vaccine	No dose	No dose
	Previously vaccinated with monovalent mRNA COVID-19 vaccine		
	1 dose of monovalent vaccine	1 dose. Administer: • Dose 2 at least 4–8 weeks¶ after Dose 1	0.25 mL/25 µg from the vial with a blue cap and gray label border.
	2 doses of monovalent vaccine	1 dose. Administer: • Dose 3 at least 8 weeks (2 months) after Dose 2	0.2 mL/10 µg from the vial with a dark pink cap and yellow label border
	At least 1 dose of monovalent vaccine and 1 dose of bivalent vaccine	No dose	No dose
6 years and older	Unvaccinated: 0 doses	1 dose now**	6 through 11 years: 0.25 mL/25 µg from the vial with a blue cap and gray label border 12 years and older: 0.50 mL/50 µg from the vial with a blue cap and gray label border
	1 or more doses of monovalent vaccine	1 dose. Administer: • Vaccine at least 8 weeks (2 months) after the previous dose**	
	At least 1 dose of bivalent vaccine	No dose**	No dose**

* Refer to [CDC's Interim Clinical Considerations](#) for specific guidance on interchangeability of vaccine products for all ages.

† Persons with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ CDC recommends bivalent vaccine doses from the same manufacturer for children 6 months through 5 years of age who are unvaccinated (no previous doses of COVID-19 vaccine) if more than 1 dose is recommended. In the following exceptional situations, a different age-appropriate COVID-19 vaccine may be administered when FDA authorization requires that a vaccine from the same manufacturer be used and a VAERS report is not required:

- Same vaccine not available
- Previous dose unknown
- Person would otherwise not complete the vaccination series
- Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication

§ Children ages 6 months through 4 years who received bivalent vaccines from different manufacturers for the first 2 doses of an mRNA COVID-19 vaccine series should follow a 3-dose schedule. A third dose of either mRNA vaccine (Moderna or Pfizer-BioNTech) should be administered at least 8 weeks after the second dose.

¶ An 8-week interval between the first and second doses of COVID-19 vaccines might be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it may reduce the small risk of myocarditis and pericarditis associated with these vaccines.

** Adults 65 years of age and older: May receive 1 additional bivalent mRNA vaccine dose at least 4 months after the first dose of a bivalent mRNA vaccine.

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 1b. For Most People (those who are NOT moderately to severely immunocompromised)

Bivalent Pfizer-BioNTech COVID-19 Vaccine:* Monovalent Pfizer-BioNTech vaccine is no longer recommended and should not be used.

Vaccine type: mRNA

Age	Vaccination History	Bivalent Vaccine Schedule [†]	Administer	
6 months through 4 years^{‡§}	Unvaccinated: 0 doses	3 doses. Administer: • Dose 1 now • Dose 2 at least 3–8 weeks [¶] after Dose 1 • Dose 3 at least 8 weeks (2 months) after Dose 2	0.2 mL/3 μ g from the vial with a maroon cap	
	1 dose of bivalent vaccine	2 doses. Administer: • Dose 2 at least 3–8 weeks [¶] after Dose 1 • Dose 3 at least 8 weeks (2 months) after Dose 2		
	2 doses of bivalent vaccine	1 dose. Administer: • Dose 3 at least 8 weeks (2 months) after Dose 2		
	At least 3 doses of bivalent vaccine	No dose	No dose	
	Previously vaccinated with monovalent mRNA COVID-19 vaccine			
	1 dose of monovalent vaccine	2 doses. Administer: • Dose 2 at least 3–8 weeks [¶] after Dose 1 • Dose 3 at least 8 weeks (2 months) after Dose 2	0.2 mL/3 μ g from the vial with a maroon cap	
	2 doses of monovalent vaccine	1 dose. Administer: • Dose 3 at least 8 weeks (2 months) after Dose 2		
	At least 1 dose of monovalent vaccine and 1 dose of bivalent vaccine	No dose	No dose.	
5 years and older[‡]	Unvaccinated: 0 doses	1 dose now**	5 through 11 years: 0.2 mL/10 μ g from the vial with an orange cap 12 years and older: 0.3 mL/30 μ g from the vial with a gray cap	
	1 dose or more doses of monovalent vaccine [§]	1 dose. Administer: • Vaccine at least 8 weeks (2 months) after the previous dose**		
	At least 1 dose of bivalent vaccine	No dose**	No dose**	

* Refer to [CDC's Interim Clinical Considerations](#) for specific guidance on interchangeability of vaccine products for all ages.

† Persons with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ CDC recommends bivalent vaccine doses from the same manufacturer for children 6 months through 5 years of age who are unvaccinated (no previous doses of COVID-19 vaccine) if more than 1 dose is recommended. In the following exceptional situations, a different age-appropriate COVID-19 vaccine may be administered when FDA authorization requires that a vaccine from the same manufacturer be used and a VAERS report is not required:

- Same vaccine not available
- Previous dose unknown
- Person would otherwise not complete the vaccination series
- Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication

§ Children ages 6 months through 4 years who received bivalent vaccines from different manufacturers for the first 2 doses of an mRNA COVID-19 vaccine series should follow a 3-dose schedule. A third dose of either mRNA vaccine (Moderna or Pfizer-BioNTech) should be administered at least 8 weeks after the second dose.

¶ An 8-week interval between the first and second doses of COVID-19 vaccines might be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it may reduce the small risk of myocarditis and pericarditis associated with these vaccines.

** Adults 65 years of age and older: May receive 1 additional bivalent mRNA vaccine dose at least 4 months after the first dose of a bivalent mRNA vaccine.

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule for Persons 6 Months of Age and Older



Table 1c. For Most People (those who are NOT moderately to severely immunocompromised)

Novavax* (Monovalent vaccine) Type: Protein Sub-Unit			
Age	Vaccination History	Vaccine Schedule [†]	Administer
12 years and older	1 or more doses of monovalent Novavax vaccine	1 dose bivalent mRNA vaccine at least 8 weeks (2 months) after Dose 2 [‡]	Moderna: 0.50 mL/50 <i>ug</i> from the vial with a blue cap and gray label border. OR Pfizer-BioNTech: 0.3 mL/30 <i>ug</i> from the vial with a gray cap
	At least 1 dose of bivalent vaccine	No dose [‡]	No dose [‡]

* Novavax COVID-19 Vaccine remains authorized to provide a 2-dose primary series (separated by at least 4–8 weeks) to people ages 12 years and older. Administer 0.5 mL/5 μ g rS and 50 μ g of Matrix-M™ adjuvant vaccine from a vial with a royal blue cap. A booster dose is authorized in limited situations to people ages 18 years and older who completed the primary series using any COVID-19 vaccine, have not received any previous booster dose(s), and are unable (i.e., vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a dose. This dose is administered at least 6 months after completion of any primary series.

[†] Persons with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

[‡] Adults 65 years of age and older: May receive 1 additional bivalent mRNA vaccine dose at least 4 months after the first dose of a bivalent mRNA vaccine.

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 2a. **People Who are Moderately to Severely Immunocompromised**

Bivalent Moderna COVID-19 Vaccine:* Monovalent Moderna vaccine is no longer recommended and should not be used. Vaccine type: mRNA				
Age	Vaccination History	Bivalent Vaccine Schedule	Administer	
6 months and older[†]	Unvaccinated: 0 doses	3 doses. Administer: • Dose 1 now. • Dose 2 at least 4 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. [‡]	6 months through 11 years: 0.25 mL/25 µg from the vial with a blue cap and gray label border. 12 years and older: 0.50 mL/50 µg from the vial with a blue cap and gray label border.	
	1 dose of bivalent vaccine only	2 doses. Administer: • Dose 2 at least 4 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. [‡]		
	2 doses of bivalent vaccine	1 dose. Administer: • Dose 3 at least 4 weeks after Dose 2. [‡]		
	3 doses of bivalent vaccine	See footnote [‡]	6 months through 5 years: 0.2mL/10 µg from the vial with a dark pink cap and yellow label border [‡] . 6 through 11 years: 0.25 mL/25 µg from the vial with a blue cap and gray label border. 12 years and older: 0.50 mL/50 µg from the vial with a blue cap and gray label border.	
	Previously vaccinated with monovalent mRNA COVID-19 vaccine			
	1 dose of monovalent vaccine	2 doses. Administer: • Dose 2 at least 4 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2. [‡]	6 months through 11 years: 0.25 mL/25 µg from the vial with a blue cap and gray label border.	
	2 doses of monovalent vaccine	1 dose. Administer: • Dose 3 at least 4 weeks after Dose 2. [‡]	12 years and older: 0.50 mL/50 µg from the vial with a blue cap and gray label border.	
	3 doses of monovalent vaccine	1 dose. Administer: • Dose 4 at least 8 weeks after Dose 3. [‡]	6 months through 5 years: 0.2mL/10 µg from the vial with a dark pink cap and yellow label border.	
	3 doses of monovalent vaccine and 1 dose of bivalent vaccine	See footnote [‡]	6 through 11 years: 0.25 mL/25 µg from the vial with a blue cap and gray label border. 12 years and older: 0.50 mL/50 µg from the vial with a blue cap and gray label border.	

* Refer to [CDC's Interim Clinical Considerations](#) for specific guidance on interchangeability of vaccine products for all ages.

† CDC recommends bivalent vaccine doses from the same manufacturer for children 6 months through 5 years of age who are unvaccinated (no previous doses of COVID-19 vaccine) if more than 1 dose is recommended. In the following exceptional situations, a different age-appropriate COVID-19 vaccine may be administered when FDA authorization requires that a vaccine from the same manufacturer be used and a VAERS report is not required:

- Same vaccine not available
- Previous dose unknown
- Person would otherwise not complete the vaccination series
- Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication

‡ People who are moderately or severely immunocompromised have the option to receive 1 additional dose of a bivalent mRNA vaccine at least 2 months following the last recommended bivalent mRNA COVID-19 vaccine dose. Further additional bivalent dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose. Refer to [CDC's Interim Clinical Considerations for the Use of COVID-19 Vaccines](#) for dosage guidance.

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule for Persons 6 Months of Age and Older



Table 2b. **People Who are Moderately to Severely Immunocompromised**

Bivalent Pfizer-BioNTech COVID-19 Vaccine:* Monovalent Pfizer-BioNTech vaccine is no longer recommended and should not be used.
Vaccine type: mRNA

Age	Vaccination History	Bivalent Vaccine Schedule	Administer	
6 months through 4 years[†]	Unvaccinated: 0 doses	3 doses. Administer: <ul style="list-style-type: none"> • Dose 1 now. • Dose 2 at least 3 weeks after Dose 1. • Dose 3 at least 8 weeks (2 months) after Dose 2.[‡] 	0.2 mL/3 μ g from the vial with a maroon cap	
	1 dose of bivalent vaccine	2 doses. Administer: <ul style="list-style-type: none"> • Dose 2 at least 3 weeks after Dose 1. • Dose 3 at least 8 weeks (2 months) after Dose 2.[‡] 		
	2 doses of bivalent vaccine	1 dose. Administer: <ul style="list-style-type: none"> • Dose 3 at least 8 weeks (2 months) after Dose 2.[‡] 		
	3 doses of bivalent vaccine	See footnote [‡]		
	Previously vaccinated with monovalent mRNA COVID-19 vaccine			
	1 dose of monovalent vaccine	2 doses. Administer: <ul style="list-style-type: none"> • Dose 2 at least 3 weeks after Dose 1. • Dose 3 at least 8 weeks (2 months) after Dose 2.[‡] 		
	2 doses of monovalent vaccine	1 dose. Administer: <ul style="list-style-type: none"> • Dose 3 at least 8 weeks (2 months) after Dose 2.[‡] 		
	3 doses of monovalent vaccine	1 dose. Administer: <ul style="list-style-type: none"> • Dose 3 at least 8 weeks (2 months) after Dose 2.[‡] 		
At least 1 dose of monovalent vaccine and 1 dose of bivalent vaccine	See footnote [‡]			
5 years[†] and older	Unvaccinated: 0 doses	3 doses. Administer: <ul style="list-style-type: none"> • Dose 1 now. • Dose 2 at least 3 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2.[‡] 	5 through 11 years: 0.2 mL/10 μ g from the vial with an orange cap	
	1 dose of bivalent vaccine	2 doses. Administer: <ul style="list-style-type: none"> • Dose 2 at least 3 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2.[‡] 		
	2 doses of bivalent vaccine	1 dose. Administer: <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after Dose 2.[‡] 		
	3 doses of bivalent vaccine	See footnote [‡]		
	Previously vaccinated with monovalent mRNA COVID-19 vaccine			12 years and older: 0.3 mL/30 μ g from the vial with a gray cap
	1 dose of monovalent vaccine	2 doses. Administer: <ul style="list-style-type: none"> • Dose 2 at least 3 weeks after Dose 1. • Dose 3 at least 4 weeks after Dose 2.[‡] 		
	2 doses of monovalent vaccine	1 dose. Administer: <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after the previous dose.[‡] 		
	3 doses of monovalent vaccine	1 dose. Administer: <ul style="list-style-type: none"> • Dose 4 at least 8 weeks (2 months) after Dose 3.[‡] 		
At least 1 dose of monovalent vaccine and 1 dose of bivalent vaccine	See footnote [‡]			

* Refer to [CDC's Interim Clinical Considerations](#) for specific guidance on interchangeability of vaccine products for all ages.

[†] CDC recommends bivalent vaccine doses from the same manufacturer for children 6 months through 5 years of age who are unvaccinated (no previous doses of COVID-19 vaccine) if more than 1 dose is recommended. In the following exceptional situations, a different age-appropriate COVID-19 vaccine may be administered when FDA authorization requires that a vaccine from the same manufacturer be used and a VAERS report is not required: Same vaccine not available; or previous dose unknown; or person would otherwise not complete the vaccination series; or person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication

[‡] People who are moderately or severely immunocompromised have the option to receive 1 additional dose of a bivalent mRNA vaccine at least 2 months following the last recommended bivalent mRNA COVID-19 vaccine dose. Further additional bivalent dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose. Refer to [CDC's Interim Clinical Considerations for the Use of COVID-19 Vaccines](#) for dosage guidance.

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule for Persons 6 Months of Age and Older



Table 2c. **People Who are Moderately to Severely Immunocompromised**

Novavax* (Monovalent vaccine) Type: Protein Sub-Unit			
Age	Vaccination History	Vaccine Schedule	Administer
12 years and older	1 or more doses of monovalent Novavax vaccine	1 dose bivalent mRNA vaccine at least 8 weeks (2 months) after Dose 2 [†]	Moderna: 0.50 mL/50 ug from the vial with a blue cap and gray label border. OR Pfizer-BioNTech: 0.3 mL/30 ug from the vial with a gray cap

* Novavax COVID-19 Vaccine remains authorized to provide a 2-dose primary series (separated by at least 4–8 weeks) to people ages 12 years and older. Administer 0.5 mL/5 ug rS and 50 µg of Matrix-M™ adjuvant vaccine from a vial with a royal blue cap. A booster dose is authorized in limited situations to people ages 18 years and old who completed the primary series using any COVID-19 vaccine, have not received any previous booster dose(s), and are unable (i.e., vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a dose. This dose is administered at least 6 months after completion of any primary series.

† People who are moderately or severely immunocompromised have the option to receive 1 additional dose of a bivalent mRNA vaccine at least 2 months following the last recommended bivalent mRNA COVID-19 vaccine dose. Further additional bivalent dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose. Refer to CDC's Interim Clinical Considerations for the Use of COVID-19 Vaccines for dosage guidance.